A two year old child presents for treatment after a brief seizure. The seizure is attributed to an ingestion; the child is accompanied by a partially chewed cough-suppressing vapor patch applied earlier for viral respiratory symptoms. The patch contains camphor, eucalyptus oil and menthol, formulated for chest application in order to entrain medicinal vapors in the nose and mouth. This single case prompted Health Canada in May 2006 to quickly issue a product warning regarding the ability of small children to remove the patches and place them in their mouths. One month later, the maker of the product, Novartis Consumer Health, along with the FDA, notified patients, pharmacists, and healthcare providers of a nationwide recall of all Triaminic® Vapor Patch products.
This single incident was the tipping point in getting over 50 million patches sold since 2000 discontinued. Although the medicinal value of all cough and cold preparations is questionable, there were no deaths or permanent sequelae associated with this particular product. This is the power of the case report; one that had not even made it to peer review and publication. Although case reports may be delegated to the lowest rung of the evidenced-based ladder, they definitely have the ability, especially in toxicology, to influence patient care.
In medicine, case reports have traditionally been used to present new clinical findings. But as early as the 1990s, case reports and series were losing favor among general medical journals. Among JAMA, NEJM, and Lancet, the proportion of case reports decreased from 42% to 8% from 1971-1991 [2] . Some journals, such as the BMJ, refuse to publish them. The main complaint in publishing such reports has been the unreliability of information tendered for diagnosis, prognosis, and treatment of various conditions. Regardless, the Journal of Medical Toxicology will continue to publish case reports because of their essential value in the field of toxicology, especially if they meet reasonable criteria for causality.
Case reports are needed for picking up the novelty in medicine, particularly in toxicology. Every supratherapeutic ingestion or toxic exposure is a new clinical finding that cannot be reproduced in a controlled setting. In addition, case reports are useful in identifying potential drug interactions, particularly for new pharmaceutical combinations [3] . Finally, we will never have randomized clinical trials looking at treatments for every possible manifestation of toxicity.
Even though case reports are not the best scientific evidence, they are often the earliest evidence of a new phenomenon. This is especially true for adverse events, which journals have a duty to disseminate [4] . In such cases the linkage should be reasonable and include temporal relation, dose response, and the effect of withdrawal as well as reintroduction, if available [5] . Toxicologist need to consider the physiological rationale for the adverse event or toxicity reported, which is the point of most discussions in case reports.
One great example of the influence of adverse events was with telithromycin. In 2005, a 26 year old man was prescribed telithromycin for presumed complicated sinusitis [6] . He returned to the emergency department two weeks later with jaundice and gastrointestinal bleeding. Within two days of admission he arrested in refractory acidosis. His autopsy revealed massive hepatic necrosis with lymphocytic infiltration. Originally marketed as a breakthrough drug in treating upper respiratory infections caused by resistant streptococcus, the drug was approved by the FDA in spite of questionable data. This simple case, published along with two other cases of hepatic toxicity from the drug, prompted a more in depth look at the data and cautions associated with this new antibiotic [7] . The end result was charges of fraud regarding some of the principle investigators and an FDA investigation into the safety of the drug.
Case reports do more than describe unusual adverse events. They can even impact treatment of poisonings. A case series of potentially lethal chloroquine overdoses showed that 10 out of 11 survived when treated with a combination of diazepam, epinephrine, and mechanical ventilation [88] . Formal treatment recommendations for these overdoses now reflect this data. Similarly, the use of insulin therapy for CCB toxicity and octreotide for sulfonylurea overdoses are all based on retrospective case series [9, 10] . Because of the paucity of clinical trials in toxicology, case reports actually help direct the decision in patient care.
Case reports are not considered research and the Journal of Medical Toxicology does not require Institutional Review Board (IRB) approval. Case reports do not meet the Department of Health and Human Services definition of research, which is a "systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge" [11] . An exception to this rule would be if an activity involves more than a few clinical cases in an analytical activity, crossing over into the realm of research. If a paper requires statistics, the researcher is probably engaging in research. In that case, IRB review would be required, although it may result in a simple letter of exemption.
Case reports, although delegated to the rear of the evidenced based bus, are an essential part of toxicology. As Karl Popper stated, science only advances when unexpected observations cause a frame shift in our previously held beliefs [12] . In the realm of toxicology, every poisoning and subsequent response to treatment is a new observation. Without case reports, toxicologists would not be able to keep up with adverse effects and drug interactions. Therefore, in order to safeguard the public and advance our specialty, we need to continue to embrace the well written case report.
The author has no potential financial conflicts of interest to report.
